We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. Show more
HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024...
– Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024 –– Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity –– Abiprubart...
– ARCALYST® (rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively – – ARCALYST 2024 net product revenue expected to be $360 - $380 million...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.68 | -3.85706182643 | 17.63 | 17.84 | 16.92 | 308483 | 17.34426065 | CS |
4 | -3.01 | -15.0801603206 | 19.96 | 20.32 | 16.92 | 343806 | 18.54957347 | CS |
12 | -1.4 | -7.62942779292 | 18.35 | 22.1 | 16.92 | 360833 | 19.55107689 | CS |
26 | 0.39 | 2.35507246377 | 16.56 | 22.1 | 14.12 | 425109 | 18.14801993 | CS |
52 | 5.12 | 43.279797126 | 11.83 | 22.1 | 10.645 | 431900 | 17.10533748 | CS |
156 | 1.56 | 10.1364522417 | 15.39 | 22.1 | 7.36 | 391883 | 14.22611947 | CS |
260 | 0.92 | 5.73923892701 | 16.03 | 33 | 5.01 | 352504 | 15.29121526 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions